Evidence map›Paper›PMID 35327472›Full record

ArticleBiomedicines2022

In Vivo Efficacy of SQ109 against

Kyung-Hwa Baek, Trong-Nhat Phan, Satish R Malwal, Hyeryon Lee, Zhu-Hong Li, Silvia N J Moreno, Eric Oldfield, Joo Hwan No

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. InhibitingPharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kyung-Hwa BaekHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Trong-Nhat PhanHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Satish R MalwalDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Hyeryon LeeHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Zhu-Hong LiCenter for Tropical and Emerging Global Diseases, Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Silvia N J MorenoCenter for Tropical and Emerging Global Diseases, Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
Eric OldfieldDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Joo Hwan NoHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Institut Pasteur Korea · KRUniversity of Georgia · USUniversity of Illinois Urbana-Champaign · US

Funding

Anti-Toxoplasma isoprenoid pathway inhibitors and the host immune responseR21AI147661 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2020 to 2021
$415k
NIAID NIH HHS R21 AI147661NIH HHS 5R21AI147661
6 · The paper itself

Abstract

SQ109 is an anti-tubercular drug candidate that has completed Phase IIb/III clinical trials for tuberculosis and has also been shown to exhibit potent in vitro efficacy against protozoan parasites including

Indexed as

in vivoLeishmania donovanimetabolitesSQ109Trypanosoma bruceiTrypanosoma cruzi

Identifiers

PMID35327472
PMCPMC8944987
OpenAlexW4220861607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.